Molecular Medicine Partnership Unit

The MMPU is a joint venture between the Medical Faculty of the University of Heidelberg and the European Molecular Biology Laboratory (EMBL).


One MMPU hallmark is that it is staffed by both institutions and each research group is headed by two or more cooperating principal investigators.

The cooperation with the EMBL includes participation in all of EMBL’s research activities, access to its scientific core facilities and affiliation with the EMBL International PhD Programme (EIPP) and the EMBL Interdisciplinary Postdocs (EIPOD) programme. Likewise, the Medical Faculty provides full access to its facilities, provides the laboratory space for the MMPU and funds scientists through its post-doc fellowship programme. Predoctoral as well as postdoctoral fellows strongly benefit from the sharing of medical and basic science expertise. The Heidelberg Research Centre for Molecular Medicine (HRCMM) is part of the Excellence Initiative II of Heidelberg University and funded fellowships (2012 – 2019)for medical students and scientifically orientated physicians to do top-level international research.

Since summer 2011, the MMPU labs are united in common space in the Otto-Meyerhof-Zentrum (OMZ) on the Medical Campus of Heidelberg University, within walking distance from the German Cancer Research Centre (DKFZ) and the Centre for Molecular Biology of Heidelberg University (ZMBH), and a short drive from EMBL.


The Molecular Medicine Partnership Unit drives innovation and its translation into medicine, leveraging its internationality and interdisciplinarity at the interface of molecular research and health care.


The Molecular Medicine Partnership Unit combines the best of two world-renowned institutions: the European Molecular Biology Laboratory and the University of Heidelberg.
Our vision is:

  • to accelerate the understanding of human diseases, leading to a better medicine with mechanism-based improvements in prevention, diagnosis and treatment
  • to train the next generation of leaders in biomedical science and patient-oriented discovery
  • to harness the power of big data for personalized medicine, integrating clinical and molecular data
  • to cooperate with the best from academia, biotechnology, pharma and other industries in a collegial, creative, bold and effective way